The 6 most recent market catalysts affecting $MDCX, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Neutral
Impact 65
Medicus Pharma Posts Phase 2 Clinical Study Report For SKNJCT‑003 On ClinicalTrials.gov, Offering Public Access To Efficacy, Safety, And Drug‑Delivery Findings
Medicus Pharma has made public the abridged Clinical Study Report for its SKNJCT-003 Phase 2 trial. This is a positive development as it increases transparency regarding the drug's…
Sep 8, 2026
Corporate Catalyst
Bullish
Impact 75
MDCX stock has given up its prior gain. Medicus Pharma shares were trading higher after the company provided a strategic update highlighting its transformation into a precision oncology-led biotechnology company.
The headline highlights a classic 'buy the rumor, sell the news' scenario or a market re-evaluation of a corporate announcement. MDCX's strategic shift to precision oncology is a s…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 85
Medicus Pharma Inks Global Licensing Deal with Pfizer Worth Over $1 Billion
Medicus Pharma (MDCX) has entered a transformative licensing agreement with Pfizer (PFE) for an early-stage melanoma drug, PF-08046031 (CD228V). This is a major positive for Medicu…
Aug 12, 2026
Corporate Catalyst
Bearish
Impact 95
Medicus Pharma Q2 EPS $(0.21) Misses $(0.13) Estimate
Medicus Pharma (MDCX) announced Q2 earnings per share of $(0.21), which missed the analyst consensus estimate of $(0.13) by a substantial 61.54%. This significant miss indicates th…
Jul 31, 2026
Corporate Catalyst
Bullish
Impact 65
EXCLUSIVE: Medicus Pharma Launches Genomics-Guided Endometriosis Study In Abu Dhabi
Medicus Pharma secured regulatory clearance from the UAE Department of Health – Abu Dhabi for its PRECISION-E2 Phase 2a clinical study of Teverelix for moderate-to-severe symptomat…
Jul 27, 2026
Corporate Catalyst
Neutral
Impact 75
Medicus Pharma Receives FDA's Study May Proceed Letter Authorization For Its Investigational New Drug For SKNJCT-005 To Start Phase 2b Clinical Study To Treat Gorlin Syndrome
Medicus Pharma announced that the FDA has issued a 'Study May Proceed' letter for its Investigational New Drug (IND) application for SKNJCT-005. This authorization allows Medicus t…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.